Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Distinct GLP1R and GIPR variants correlated with nausea/vomiting risk, with a GIPR signal appearing tirzepatide-specific and showing markedly increased vomiting odds. New studies from 23andMe suggest ...
In this episode of Pharmaceutical Executive’s podcast series Leading Edge With Ken Banta, The Vanguard Network founder and ...
China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...
GLP-1 drugs continue to dominate the pharmaceutical landscape. The medication is popular for its weight loss applications, and major pharmaceutical companies continue to introduce new versions of ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
In today's Pharmaceutical Executive Daily, Shionogi receives a contract worth up to $482 million to bolster U.S. preparedness against drug-resistant bacterial threats, Roche and C4 Therapeutics expand ...
Financially, the agreement includes a $20 million upfront payment to C4 Therapeutics, with the potential for additional ...
The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja ...
Pharmaceutical Executive: How does the complexity of obesity impact the effectiveness of GLP-1s? Mark Bagnall: This is one of ...
VESALIUS-CV data supported evolocumab reducing MACE in high-risk primary prevention diabetes over 4.8 years, reinforcing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results